<DOC>
	<DOCNO>NCT02249091</DOCNO>
	<brief_summary>Acute Myeloid Leukemia ( AML ) currently treat chemotherapy combine several drug different way inhibit cell growth . In trial , standard chemotherapeutics proven effectiveness year , Ara-C Idarubicin , combine new drug call Selinexor . Selinexor inhibit growth cancer cell keep certain protein nucleus control cell growth .</brief_summary>
	<brief_title>A Study To Evaluate Ara-C Idarubicin Combination With Selective Inhibitor Of Nuclear Export ( SINE ) Selinexor ( KPT-330 ) Patients With Relapsed Or Refractory AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Cytological histological diagnosis AML exception promyelocytic leukemia ( AML M3 ) 2 . Patients must relapsed/refractory disease ( relapse stem cell transplantation permit ) define : 1. patient &lt; PR first cycle induction chemotherapy , 2. patient &lt; CR ( ) second cycle induction chemotherapy , 3. patient relapse conventional chemotherapy 4. patient undergone single stem cell transplantation relapse AML . 3 . Men woman age ≥18 year eligible standard dose chemotherapy ( 7+3 ) ; 4 . A period least 3 week need elapse since last treatment ( exception hydroxyurea ) participate study . Hydroxyurea induction therapy reduce peripheral blast count permit prior initiation treatment protocol . Treatment may begin &lt; 3 week last treatment deem best interest patient discussion PI study ; 5 . ECOG performance status ≤ 2 6 . Serum biochemical value follow limit unless consider due leukemia : creatinine ≤2 mg/dl ; total bilirubin ≤2x ULN , unless increase due hemolysis congenital disorder ; transaminase ( SGPT SGOT ) ≤2.5x ULN . 7 . Ability swallow retain oral medication 8 . Ability understand provide sign informed consent ; 9 . Cardiac ejection fraction must &gt; /=50 % ( echocardiography ) . 10 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Treatment investigational agent within four week . 2 . Cumulative anthracycline dose ( daunorubicin equivalent ) &gt; 360 mg/m² 3 . HIV infection 4 . Presence medical psychiatric condition may limit full compliance study , include limited : 1 . Presence CNS leukemia 2 . Unresolved toxicity previous anticancer therapy incomplete recovery surgery . 5 . For patient SCT part prior treatment : 1 . Necessity immunosuppressive drug 2 . GvHD &gt; grade 1 6 . Any follow within 12 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis , thromboembolic event . 7 . Ongoing cardiac dysrhythmias NCI CTCAE &gt; /= Grade 2 . 8 . Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study . 9 . Clinically significant bleeding within 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>